Psoriatic arthritis monocyte DNA methylomes bridge joint and skin inflammatory pathways across rheumatoid arthritis and psoriasis - PubMed
3 hours ago
- #autoimmune diseases
- #monocyte epigenomics
- #DNA methylation
- Immune-mediated inflammatory diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) share clinical, genetic, and immunological features.
- PsA bridges joint pathology (akin to RA) and skin involvement (akin to PsO), with monocyte DNA methylation revealing common and disease-specific epigenomic traits.
- A common methylation signature across RA, PsA, and PsO involves enhancers, immune regulatory pathways, and transcription factors like interferon regulatory factors and STAT proteins.
- PsA exhibits a dual epigenomic profile, sharing features with both RA (e.g., MHC class II loci) and PsO (e.g., fibroblast growth factor receptor signaling).
- PsA's disease activity correlates with methylation changes linked to inflammasome components and cytokine signaling pathways, such as IL-23/IL-17.
- Single-cell transcriptomic analysis confirms convergent alterations in antigen presentation, interferon responses, NF-κB signaling, and fibroblast-associated genes, plus PsA-specific signatures.
- The study suggests PsA occupies a dual molecular state, bridging joint and skin autoimmunity, providing insights into disease mechanisms and classification.